Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an injectable solution for intravenous infusion. It is used in oncology to treat certain advanced solid tumours, primarily in adult patients with non‑small cell lung cancer or metastatic breast cancer.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Vinorelbine is a chemotherapy agent that interferes with microtubule dynamics in malignant cells, making it useful in specific solid‑tumour protocols.

Non‑small cell lung cancer: used as part of combination chemotherapy to inhibit tumour growth and improve progression‑free survival. Metastatic breast cancer: administered in combination regimens to control disease spread and extend overall survival.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Anemia: lowered red‑blood‑cell levels causing fatigue. - Nausea and vomiting: gastrointestinal upset common with chemotherapy. - Constipation: reduced bowel motility. - Alopecia: hair loss during treatment. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring urgent care. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm in susceptible patients.

Vinorelbine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dosing in hepatic impairment. Avoid concurrent myelosuppressive agents: increased risk of bone‑marrow suppression. Use antiemetics prophylactically: reduce nausea and vomiting. Pregnancy: contraindicated or unknown; avoid use in pregnant women. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid): - Concurrent Vinca alkaloids: additive myelosuppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased vinorelbine exposure. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): reduced drug levels. - Anticoagulants (e.g., warfarin): potential bleeding risk. - NSAIDs: may exacerbate thrombocytopenia.